NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-193-2020-0-US-01 RNASEH-ASSISTED DETECTION ASSAY FOR RNA (RADAR) US 63/077,123 Abandoned
NEI E-227-2018-0-PCT-02 Druggable Taraget to Treat Retinal Degeneration PCT PCT PCT/US2020/050540 Expired
NEI E-227-2018-0-KR-11 Druggable Taraget to Treat Retinal Degeneration KR National Stage 10-2022-7012050 Pending
NCI E-182-2019-2-CA-03 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER CA National Stage 3153096 Pending
NCI E-494-2013-0-HK-21 Methods of Preparing Anti-human Papillomavirus Antigen T Cells HK EP 42020015851.7 Issued
NCI E-227-2006-5-AU-21 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS AU DIV 2020230283 Issued
NCI E-030-2022-0-PCT-02 Anti-Viral Compositions And Methods Of Making And Using PCT PCT PCT/US2020/050200 Expired
NCI E-097-2018-0-IN-10 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN National Stage 202047039152 Pending
NCI E-097-2018-0-MX-12 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES MX National Stage MX/a/2020/009472 Pending
NCATS E-229-2016-0-US-05 PEPTIDE INHIBITORS OF PHOSPHOGLYCERATE MUTASE AND METHODS OF USE US DIV 17/016,168 Abandoned
NCI E-097-2018-0-CN-06 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES CN National Stage 201980018105.0 Pending
NCI E-097-2018-0-CA-05 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES CA National Stage 3093567 Pending
NCI E-097-2018-0-SG-15 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES SG National Stage 11202008796V Pending
NCI E-097-2018-0-ZA-17 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES ZA National Stage 2020/05571 Pending
NCI E-097-2018-0-NZ-13 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES NZ National Stage 767782 Pending
NCI E-167-2019-0-US-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY US 63/075,536 Abandoned
NCI E-081-2018-0-US-03 17-BETA-HYDROXYWITHANOLIDES AND USE THEREOF IN TREATING CANCER US National Stage 16/978,442 Pending
NIDA E-023-2018-0-EP-03 DREADD ACTUATORS EP National Stage 19706192.2 Pending
NCI E-162-2014-0-US-09 Human Monoclonal Antibodies (mAbs) Against EphA4 As Candidate Therapeutics US CON 17/012,928 Abandoned
NCI E-173-2020-0-US-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATION IN P53 US 63/074,747 Abandoned
NINDS E-025-2018-1-US-03 POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF US National Stage 16/977,897 Pending
NHLBI E-218-2016-1-US-03 Immunogens, Compositions, And Methods For Treating Dyslipidemia US National Stage 16/977,648 11633471 Issued PDF
NCI E-163-2020-0-US-01 LZK-TARGETING DEGRADERS AND METHODS OF USE US 63/073,835 Abandoned
NCI E-097-2018-0-AU-04 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES AU National Stage 2019235926 Pending
NCATS E-117-2018-0-US-03 2,6-DIMETHOXY-4-(5-PHENYL-4-THIOPHENE-2-YL-1H-IMIDAZOL-2-YL)-PHENOL (DPTIP) A SMALL MOLECULE INHIBITOR OF NEUTRAL SPHINGOMYELINASE 2 (nSMase-2) FOR THE TREATMENT OF
NEURODEGENERATIVE AND ONCOLOGIC DISEASES 		US National Stage 16/977,305 11766423 Issued PDF
NIAID E-089-2002-1-US-89 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 US DIV 17/009,448 11753627 Expired PDF
NCI E-097-2018-0-IL-09 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IL National Stage 277078 Pending
NIAID E-297-2016-2-US-07 VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES US CON 17/008,025 11390651 Issued PDF
NHLBI E-126-2020-0-US-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) US 63/072,519 Abandoned
NCATS E-084-2020-0-PCT-02 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators PCT PCT PCT/US2020/048482 Expired
NCATS E-084-2020-0-US-03 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF US National Stage 17/638,929 Pending
NIAID E-048-2020-0-PCT-02 COMPOSITIONS INCLUDING IGG Fe MUTATIONS AND USES THEREOF PCT PCT PCT/US2020/048253 Expired
NIAID E-145-2021-1-US-01 Adjuvanted Stabilized Stem Hemagglutinin Nanoparticles And Methods Of Using The Same To Induce Broadly Neutralizing Antibodies Against Influenza US 63/071,244 Abandoned
NCATS E-014-2022-0-US-01 HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF US 63/071,334 Abandoned
NCATS E-253-2017-0-US-03 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME US National Stage 16/976,012 11649218 Issued PDF
NCI E-171-2018-9-US-06 MODIFIED CELLS AND METHODS OF THERAPY US CON 17/003,081 11583556 Issued PDF
NCI E-029-2022-1-US-01 Q-Griffithsin Nasal Spray US 63/070,375 Abandoned
NCI E-182-2019-1-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER US 63/070,739 Abandoned
NCI E-192-2020-1-US-01 USE OF AGONISTS TO AUGMENT CART FUNCTION IN SOLID TUMORS US 63/069,649 Abandoned
NIAID E-034-2018-0-US-08 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE US National Stage 16/971,826 11760790 Issued PDF
NCI E-266-2011-0-EP-37 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage EP DIV 20192082.4 Pending
NCI E-109-2020-0-US-01 HIGH-THROUGHPUT GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES US 63/068,458 Abandoned
NCI E-059-2013-0-AU-13 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor AU DIV 2020220209 Abandoned
NEI E-091-2018-0-US-06 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION US National Stage 16/971,288 Pending
NCI E-248-2020-0-EP-04 Protein Panels For The Early Diagnosis/Prognosis Of Aggressive Prostate Cancer EP National Stage 20855632.4 Pending
NCI E-248-2020-0-PCT-02 Protein Panels For The Early Diagnosis/Prognosis Of Aggressive Prostate Cancer PCT PCT PCT/US2020/047069 Expired
NIAID E-085-2018-0-US-04 CD153 AND/OR CD30 IN INFECTION US National Stage 16/971,144 Abandoned
NCI E-248-2020-0-CA-03 Protein Panels For The Early Diagnosis/Prognosis Of Aggressive Prostate Cancer CA National Stage 3147509 Pending
NCI E-068-2018-0-EP-05 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 EP National Stage 19709154.9 Pending
NCI E-036-2018-0-US-02 HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS US National Stage 16/970,155 11787764 Issued PDF